Join

Compare · CBMG vs MRNA

CBMG vs MRNA

Side-by-side comparison of Cellular Biomedicine Group, Inc. (CBMG) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CBMG and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • MRNA carries a market cap of $20.12B.
  • MRNA has hit the wire 8 times in the past 4 weeks while CBMG has been quiet.
  • MRNA has more recent analyst coverage (25 ratings vs 0 for CBMG).
MetricCBMGMRNA
Company
Cellular Biomedicine Group, Inc.
Moderna Inc.
Price
-
$50.74-3.98%
Market cap
-
$20.12B
1M return
-
-5.22%
1Y return
-
+84.64%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
n/a
2018
News (4w)
0
8
Recent ratings
0
25
MRNA

Moderna Inc.

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.